A comprehensive reanalysis of publicly available GWAS datasets reveals an X chromosome rare regulatory variant associated with high risk for type 2 diabetes. g  e  n  c  e  R  e  s  e  a  r  c  h  I  n  s  t  i  t  u  t  e  (  I  I  I  A  )  ,  S  p  a  n  i  s  h  C  o  u  n  c  i  l  f  o  r  S  c  i  e  n  t  i  f  i  c   R  e  s  e  a  r  c  h  (  C  S  I  C  ) .
3 1 . M R C E p i d e m i o l o g y U n i t , U n i v e r s i t y o f C a m b r i d g e S c h o o l o f C l i n i c a l M e d i c i n e , C a m b r i d g e B i o m e d i c a l C a m p u s , C a m b r i d g e , C B 2 0 Q Q , U K .
4
During the last decade, hundreds of genome-wide association studies (GWAS) have been performed with the aim of providing a better understanding of the biology of complex diseases, improving their risk prediction, and ultimately discovering novel therapeutic targets 1 . However, the majority of the published GWAS just report the primary findings, which generally explain a small fraction of the estimated heritability. In order to better uncover the missing heritability, most strategies usually involve the generation of new genetic and clinical data. Very rarely, new studies are based on the revision and reanalysis of existing genetic data by applying more powerful analytic techniques and resources generated after the primary GWAS findings are published. These cost-effective reanalysis strategies are now possible, given the existence of (1) and rare variants (MAF<0.01). This increases the power to identify novel associations, as well as to refine known associated loci through fine-mapping. Moreover, the availability of public primary genetic data further allows the homogeneous integration of multiple datasets with different origins providing more accurate meta-analysis results, particularly at the low ranges of allele frequency. In contrast, common meta-analytic strategies usually involve the aggregation of summary statistics generated independently by different centers, each applying their own internal quality-control, data cleaning, genotype imputation, and association testing methodologies. Each of these steps represents a potential source of additional heterogeneity, which may ultimately result in loss of statistical power. Finally, the vast majority of reported GWAS analyses omits the X chromosome, even though it 70KforT2D: Identification of novel T2D loci with publicly available GWAS data 5 represents 5% of the genome and encodes for more than 1,500 genes 3,4 . The reanalysis of publicly available data also enables interrogation of this chromosome.
We hypothesized that a unified reanalysis of multiple publicly available datasets, applying homogeneous standardized QC, genotype imputation and association methods, as well as novel and denser sequence-based reference panels for imputation would provide new insights into the genetics and the pathophysiology of complex diseases. To test this we focused on type 2 diabetes (T2D), one of the most prevalent complex diseases for which many GWAS have been performed during the past decade 5, 6, 7, 8, 9, 10, 11 . These studies have allowed the identification of more than 100 independent loci, most of them driven by common variants, with a few exceptions 11, 12, 13 . Despite all these efforts, only a small fraction of the genetic heritability can be explained by established T2D loci, and the role of low-frequency variants, although recently proposed to be minor 14 , has still not been fully explored. The availability of large T2D genetic datasets in combination with larger and more comprehensive genetic variation reference panels 15, 16, 17, 18 , gives us the opportunity to impute a significant increased fraction of low-frequency and rare variants, and to study their contribution to the risk of developing this disease. At the same time, this strategy also allows to fine map known associated loci, increasing the chances of finding causal variants and understanding their functional impact. We therefore gathered publicly available T2D GWAS cohorts with
European ancestry, comprising a total of 13,857 T2D cases and 62,126 controls, to which we first applied harmonization and quality control protocols across the whole genome (including the X chromosome) and across samples, to later carry out imputation using 1,000 Genomes Project (1000G) 15 and UK10K 16, 17, 18 reference panels, as well as association testing. By using this strategy, we identified novel associated regions driven by common, low-frequency, and rare variants, fine-mapped and functionally annotated the existing and novel ones, and 70KforT2D: Identification of novel T2D loci with publicly available GWAS data 6 confirmed experimentally a regulatory mechanism disrupted by a novel rare and large effect variant identified at the X-chromosome.
Results

Overall analysis strategy
As shown in Figure 1 , we first gathered all T2D case-control GWAS individual-level data that was available through the EGA and dbGaP databases (i.e. Gene Environment Supplementary Figure 1 A ).
This strategy also allowed us to impute of 1,357,753 indels with good quality ( Supplementary   Figure 1 B ).
In order to take full advantage of publicly available genetic data, we used three main metaanalytic approaches to adapt to three of the most common strategies for genetic data sharing: In addition, variant set enrichment analysis of the T2D-associated credible sets across regulatory elements defined in isolated human pancreatic islets showed a significant enrichment for active regulatory enhancers (Supplementary Figure 4) , suggesting that causal SNPs within associated region have a regulatory function, as previously reported 23 .
Identification, fine-mapping and functional characterization of novel and previously known loci
The three association strategies allowed us to finally identify 57 genome-wide significant associated loci (p≤5×10 -8 ), of which seven were not previously reported as associated with T2D ( 18.4% posterior probability of being causal.
To prioritize causal variants within all the identified associated loci, we annotated their corresponding credible sets using the variant effector predictor (VEP) for coding variants
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(Supplementary Table 7) , and the Combined Annotation Dependent Depletion (CADD) tool for non-coding variation (Supplementary Table 8) 28 . Additionally, we tested the effect of all variants on expression across multiple tissues by interrogating GTEx 29 and RNA-sequencing gene expression data from pancreatic islets 30 .
70KforT2D: Identification of novel T2D loci with publicly available GWAS data 1 0
Identification of new signals driven by common variants
Beyond the detailed characterization of the known T2D associated regions, we also identified novel loci, among which, five were driven by common variants linked to modest effect sizes (1.06 < OR <1.12; Table adiponectin levels, fasting insulin, and non-alcoholic fatty liver disease 31, 32, 33, 34, 35, 36 . Among the genes of this locus, LYPLAL1, which encodes for lysophospholypase-like 1, appears as the most likely effector gene, as it has been found to be downregulated in mouse models of diet-induced obesity and upregulated during adipogenesis 37 .
Second, a novel locus at chromosome 9q34. 
Identification of a new signal driven by a low-frequency variant
We selected all low-frequency (0.01≤MAF<0.05) variants with p≤1×10 -4 in the 70KforT2D meta-analysis that were annotated as altering protein-coding variants according to VEP. This resulted in 15 coding variants that were meta-analyzed with exome array and whole-exome sequencing data from a total of ~97,000 individuals 19, 20, 21 after excluding the overlapping cohorts between the different datasets. This analysis highlighted a novel genome-wide association driven by a low-frequency missense variant (Ser58Phe) within the EHMT2 gene 70KforT2D: Identification of novel T2D loci with publicly available GWAS data , Supplementary Table 9 ). In addition, this same variant is also associated with the expression of the first and second exon of the CLIC1 mRNA in pancreatic islet donors
; Supplementary Table 10) . Interestingly, CLIC1
has been reported as a direct target of metformin by mediating the anti-proliferative effect of this drug in human glioblastoma 55 . All these findings support CLIC1, as an additional possible effector transcript, likely driven by rs115333512.
Identification of a novel rare variant in the X chromosome associated with 2.7-fold increased risk for T2D
As for many other complex diseases, the majority of published large-scale T2D GWAS studies have omitted the analysis of the X chromosome, with the notable exception of the identification of a T2D associated region near the DUSP9 gene in 2010
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. To fill this gap, we tested the X chromosome genetic variation for association with T2D. To account for heterogeneity of the effects and for the differences in imputation performance between males and females, the association was stratified by sex and tested separately, as well as together by meta-analyzing the results from males and females. This analysis was able to replicate the DUSP9 locus, not only through the known rs5945326 variant (OR=1.15, p=0.049), but also 70KforT2D: Identification of novel T2D loci with publicly available GWAS data Figure 3A ). We tested the accuracy of the imputation of this variant by comparing the imputed results from the same individuals genotyped by two different platforms (see Online Methods) and found that the imputation for this variant was highly accurate in males, and when using UK10K, but not in females, or when using 1000G (R Whether this association is specific to men or whether it also affects female carriers remains to be clarified, since the imputation for this variant in females was not accurate enough.
To further validate this association and to discard potential imputation artifacts, we next analyzed two independent cohorts by performing imputation with the UK10K reference panel ) ( Figure   3B ), and revealed a strong degree of heterogeneity (heterogeneity p het =0.002), which appeared to be driven by the replication cohorts. Within one of the case-control studies there was a nested cohort study; this study, the Inter99 prospective cohort, consisted of 1,652 non70KforT2D: Identification of novel T2D loci with publicly available GWAS data 1 4 diabetic male subjects, of whom 158 developed T2D after eleven years of follow-up.
Analysis of incident diabetes in this cohort, confirmed the association with the same allele as previously seen in the case-control studies, with carriers of the rare T allele having increased risk of developing incident diabetes, compared to the C carriers (Cox-proportional Hazards Ratio (HR)=3.17 [1.3-7.7] , p=0.011, Figure 3C ): in fact, nearly 30% carriers of the T risk allele developed incident T2D during 11 years of follow-up, compared to only ~10% of noncarriers.
In order to gain further support for this association, we thoroughly compared the clinical and demographic characteristics of the discovery and replication datasets in an attempt to understand the strong degree of heterogeneity observed when adding the replication datasets.
We found that some of the replication datasets contained control subjects that were significantly younger than the average age at onset of T2D reported in this study and in Figure 9) . Since in the Inter99 prospective cohort we observed that 30% of subjects developed incident T2D over 11 years of follow-up, we performed an additional analysis using a stricter definition of controls, in order to avoid the presence of pre-diabetes or individuals that may further develop diabetes after reaching the average age at onset. We therefore applied two additional exclusion criteria in order to obtain a stricter set of controls:
(i) excluding subjects younger than 55 years old, and (ii) restricting the analysis, when possible, to individuals with measured 2 hours plasma glucose values during oral glucose tolerance test (OGTT) below 7.8 mmol/l, which is employed to diagnose impaired glucose tolerance (pre-diabetes), a strong risk factor for developing T2D 60 . We repeated the metaanalysis using the first filtering criterion for controls for both the discovery and replication 70KforT2D: Identification of novel T2D loci with publicly available GWAS data Figure 3D ). These results therefore support the existence of a genetic association with T2D is driven by a rare variant at X chromosome.
The rs146662075 T risk allele is associated with 5-fold greater enhancer activity and disruption of allele specific nuclear protein binding.
We next explored the possible molecular mechanism behind this association by using signal of both H3K27ac and AGTR2 RNA-seq (but not SLC6A14) expression in fetal muscle ( Figure 4A ).
We next studied whether the region encompassing the rs146662075 variant could act as a transcriptional enhancer and whether its activity was allele-specific. For this, we linked the DNA region, with either the T (risk) or the C (common) allele, to a minimal promoter and performed luciferase assays in a mouse myoblast cell line. The luciferase analysis showed an average 4.4 fold increased activity for the disease-associated T allele, compared to the expression measured with the common C allele, suggesting an activating function of the T allele, or a repressive function of the C allele ( Figure 4B ). Consistent with these findings, electrophoretic mobility shift assays using nuclear protein extracts from mouse myoblast cell lines, differentiated myotubes, and human fetal muscle cell line, revealed sequence-specific binding activity of the C allele, but not of the rare T allele ( Figure 4C ). Overall, these data indicate that the risk T allele prevents binding by a nuclear protein that is associated with decreased activity of an AGTR2-linked enhancer.
Discussion
To date, a large fraction of GWAS datasets have been made publicly available through repositories such as dbGaP and EGA. However, how these resources are useful to increase the knowledge of the genetic factors contributing to disease susceptibility has not been fully explored. In this study, we demonstrate the utility of these publicly available resources. By harmonizing and reanalyzing existing and publicly available T2D GWAS data, and by performing genotype imputation with two whole-genome sequence-based reference panels,
we have been able to explore deeply the genetic architecture of T2D. This strategy allowed us to impute and test for association with T2D more than 15 million of high quality imputed variants, including low-frequency, rare, and small insertions and deletions across chromosomes 1 to 22 and X.
70KforT2D: Identification of novel T2D loci with publicly available GWAS data
The reanalysis of these data confirmed a large fraction of already known T2D loci, for which we identify and propose novel potential causal variants by fine-mapping and functionally annotating each locus. Our in-depth characterization of each of these loci reached an improved accuracy over prior efforts, providing for the first time a comprehensive coverage of structural variants, which point to previously unobserved candidate causal variants in known and novel loci.
This reanalysis also allowed us to identify seven novel associations driven by common variants in or near LYPLAL1, NEUROG3, CAMKK2, ABO and GIP; a low-frequency variant in EHMT2, and one rare variant in the X chromosome. This rare variant identified in Xq23 chromosome, was located near the AGTR2 gene, and showed a nearly three-fold increased risk for T2D in males, which represents, to our knowledge, the largest effect size identified so far in Europeans, and complements other large effect size variants identified in other specific populations 11, 12 .
This study also highlights the importance of a strict classification of both cases and controls in order to identify rare variants associated with disease, as our initial discovery for the Xq23 locus was not replicated when using the standard classification of cases and controls (based on fasting plasma glucose or glycated hemoglobin, HbA1c), but only when reclassifying the control group by restricting it to non-diabetic individuals older than 55 years (average age at onset of T2D), and with confirmed normal glucose tolerance using the stricter OGTT measure. This is in line with previous results obtained for a T2D population specific variant found in Inuit within the TBC1D4 gene, which was only significant when using OGTT as criteria for classifying cases and controls, but not when using HbA1c
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. Overall, beyond our significant contribution to the understanding of the molecular basis of T2D, our study also highlights the potential of the reanalysis of public data, as a complement to large studies using newly-generated data. This study will inform the open debate in favor of pushing data-sharing and democratization initiatives 71,72 , highlighting their importance for the study of the genetics and pathophysiology of complex diseases, which may lead to new preventive and therapeutic applications.
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Figure 1: Discovery and replication strategy. Publicly available GWAS datasets representing a total of 12,931 cases and 57,196 controls (70KforT2D) were first quality controlled, phased and imputed using 1000G and UK10K separately. For those variants that were present in the DIAGRAM trans-ethnic meta-analysis we used the summary statistics to meta-analyze our results with the cohorts that had no overlap with any of the cohorts included in the DIAGRAM trans-ethnic meta-analysis. With this first meta-analysis we discovered four novel loci (within magenta panels). For the rest of the variants we meta-analyzed all the 70KforT2D datasets, which resulted in two novel loci (in blue panels). All the variants that were coding and that showed a p-value ≤ 1x10 -4 were tested for replication by interrogating the summary statistics in the Type 2 Diabetes Knowledge Portal (T2D Portal) (http://www.type2diabetesgenetics.org/). This resulted in a novel low-frequency variant in the EHMT2 gene (highlighted with a green panel). Figure 1 ) and were depicted using different colors. HapMap variants were meta-analyzed using the Trans-Ethnic summary statistics from the DIAGRAM study and our meta-analysis based on the Genetic Epidemiology Research on Aging (GERA) cohort and the Northwestern NuGENE Project and that resulted in novel associations depicted in magenta. The rest of non-HapMap variants meta-analyzed using the full 70KforT2D cohort are represented in grey, highlighting in light blue the fraction of novel GWAS-significant variants. Coding low-frequency variants meta-analyzed using the 70KforT2D and the T2D Portal data that resulted in novel GWAS-significant associations are depicted in green. The shaded area of the QQ-plot indicates the 95% confidence interval under the null and a density function of the distribution of the p-values was plotted using a dashed line. The λ is a measure of the genomic inflation and corresponds to the observed median χ 2 test statistic divided by the median expected χ 2 test statistic under the null hypothesis. The Manhattan plot, representing the -log 10 p-values were colored as explained in the QQ-plot. All known GWAS-significant associated variants within known T2D genes are also depicted in red. X-chromosome results for females (F), males (M) and all individuals (A) are also included.
Figure 3: Discovery and replication of rs14666075 association signal. Forest plot for the rs146662075 variant using (A) the discovery cohorts and when including also (B) the replication datasets. Cohort-specific odds ratios are denoted by boxes proportional to the size of the cohort and 95% CI error bars. The combined OR estimate for all the datasets is represented by a green diamond, where the diamond width corresponds to 95% CI bounds. The p-value for the meta-analysis (Meta P) and for the heterogeneity (Het P) of odds ratio is shown. C) Plot showing the cumulative incidence of type 2 diabetes for an 11 years followup. The red line represents the T carriers and in light blue, C carriers are represented (n=1,652, cases=158.). D) Forest plot after excluding controls younger than 55 years old and OGTT>7.8 mmol/l in both the discovery and replication cohorts when available. 
